{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:55Z","timestamp":1787028775291,"version":"build-2736575974"},"reference-count":152,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Chronic pain conditions have a high socio-economic impact and represent a burden for patients, and their management is a challenge for healthcare professionals. Chronic migraine is one of the chronic primary headache disorders, which belong to chronic primary pain syndromes as per the new concept of multiple parenting. The aims of this review were to provide an overview of the latest classification systems involving both entities, the epidemiological data, and the currently recommended prophylactic treatment options for chronic migraine. Randomized controlled clinical trials, meta-analyses, real-world data, and review articles were analyzed. Chronic migraine is a prevalent and highly burdensome disease and is associated with high headache-related disability and worsening health-related quality of life. Treatment of chronic migraine includes pharmacological or, in drug-refractory cases, non-pharmacological (e.g., neuromodulatory) approaches. Among pharmacological treatment options, injectable botulinum toxin type A and calcitonin gene-related peptide-targeting human and fully humanized monoclonal antibodies (i.e., eptinezumab, erenumab, fremanezumab, and galcanezumab) are highly recommended in the preventive treatment of chronic migraine. Novel migraine-specific therapies offer a solution for this devastating and difficult-to-treat chronic pain condition.<\/jats:p>","DOI":"10.3390\/life13030665","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T06:55:16Z","timestamp":1677567316000},"page":"665","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review"],"prefix":"10.3390","volume":"13","author":[{"given":"D\u00e9lia","family":"Szok","sequence":"first","affiliation":[{"name":"Department of Neurology, Albert Szent-Gy\u00f6rgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Cs\u00e1ti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Szent-Gy\u00f6rgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Szent-Gy\u00f6rgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary"},{"name":"ELKH-SZTE Neuroscience Research Group, Semmelweis u. 6, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Tajti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Szent-Gy\u00f6rgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/j.pain.0000000000001390","article-title":"The IASP classification of chronic pain for ICD-11: Chronic primary pain","volume":"160","author":"Nicholas","year":"2019","journal-title":"Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: A narrative review","volume":"20","author":"Agostoni","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cell.2018.11.049","article-title":"CGRP Antibodies as Prophylaxis in Migraine","volume":"175","author":"Edvinsson","year":"2018","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: Epidemiology, Burden, and Comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: Risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat. Reviews. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/head.14103","article-title":"Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study","volume":"61","author":"Buse","year":"2021","journal-title":"Headache"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/head.12878","article-title":"A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability","volume":"56","author":"Lipton","year":"2016","journal-title":"Headache"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1212\/WNL.0000000000004177","article-title":"Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study","volume":"89","author":"Scher","year":"2017","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gaul, C., Schmidt, T., Czaja, E., Eismann, R., and Zierz, S. (2011). Attitudes towards complementary and alternative medicine in chronic pain syndromes: A questionnaire-based comparison between primary headache and low back pain. BMC Complement. Altern. Med., 11.","DOI":"10.1186\/1472-6882-11-89"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/head.14129","article-title":"Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study","volume":"61","author":"Barad","year":"2021","journal-title":"Headache"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/head.13613","article-title":"Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","article-title":"Medication Overuse and Headache Burden: Results From the CaMEO Study","volume":"11","author":"Schwedt","year":"2021","journal-title":"Neurology. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat. Reviews. Dis. Prim."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-019-1068-y","article-title":"Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre","volume":"20","author":"Negro","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","article-title":"Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS)","volume":"51","author":"Stokes","year":"2011","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e067670","DOI":"10.1136\/bmj-2021-067670","article-title":"Management of chronic migraine","volume":"379","author":"Hovaguimian","year":"2022","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1002\/(SICI)1097-4598(1997)6+<208::AID-MUS15>3.0.CO;2-1","article-title":"Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group","volume":"6","author":"Brin","year":"1997","journal-title":"Muscle Nerve. Suppl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1526-4610.2011.01955.x","article-title":"Pathophysiology of chronic migraine and mode of action of preventive medications","volume":"51","author":"Mathew","year":"2011","journal-title":"Headache"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Torrente, A., Pilati, L., Di Marco, S., Maccora, S., Alonge, P., Vassallo, L., Lupica, A., Coppola, S., Camarda, C., and Bolognini, N. (2022). OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment. Toxins, 15.","DOI":"10.3390\/toxins15010023"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Ramon","year":"2015","journal-title":"Pain"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"ref_35","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data","volume":"42","author":"Ducros","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40122-022-00452-3","article-title":"Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review","volume":"12","author":"Blumenfeld","year":"2022","journal-title":"Pain Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine","volume":"23","author":"Khanal","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/IJGM.S70456","article-title":"Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety","volume":"8","author":"Boudreau","year":"2015","journal-title":"Int. J. Gen. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s10072-016-2665-z","article-title":"Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine","volume":"37","author":"Demiryurek","year":"2016","journal-title":"Neurol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/03331024211018137","article-title":"CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis","volume":"41","author":"Frank","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kepczynska, K., and Domitrz, I. (2022). Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches. Toxins, 14.","DOI":"10.3390\/toxins14090619"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/toxins7072659","article-title":"Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety","volume":"7","author":"Szok","year":"2015","journal-title":"Toxins"},{"key":"ref_45","first-page":"77","article-title":"Botulinum neurotoxin\u2014A therapy in migraine","volume":"65","author":"Tajti","year":"2012","journal-title":"Ideggyogy. Szle."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","article-title":"Drug safety and tolerability in prophylactic migraine treatment","volume":"14","author":"Vecsei","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"CGRP may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuroscience.2010.05.016","article-title":"Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion","volume":"169","author":"Eftekhari","year":"2010","journal-title":"Neuroscience"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/pr.108.00372","article-title":"International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor","volume":"60","author":"Hay","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31610","DOI":"10.1074\/jbc.M701790200","article-title":"Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1","volume":"282","author":"Heroux","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0165-1838(99)00024-7","article-title":"Messenger molecules and receptor mRNA in the human trigeminal ganglion","volume":"76","author":"Tajti","year":"1999","journal-title":"J. Auton. Nerv. Syst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(79)92692-8","article-title":"Neurotransmitters and the fifth cranial nerve: Is there a relation to the headache phase of migraine?","volume":"2","author":"Moskowitz","year":"1979","journal-title":"Lancet"},{"key":"ref_55","first-page":"313","article-title":"The trigemino-vascular system and migraine","volume":"40","author":"Buzzi","year":"1992","journal-title":"Pathol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(83)90402-X","article-title":"Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats","volume":"268","author":"Mayberg","year":"1983","journal-title":"Brain Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/03331024211010305","article-title":"Efficacy of erenumab in chronic migraine patients with and without ictal allodynia","volume":"41","author":"Lipton","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00702-012-0788-9","article-title":"Where does a migraine attack originate? In the brainstem","volume":"119","author":"Tajti","year":"2012","journal-title":"J. Neural Transm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nm0795-658","article-title":"Brain stem activation in spontaneous human migraine attacks","volume":"1","author":"Weiller","year":"1995","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11916-022-01087-x","article-title":"Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research","volume":"26","author":"Lin","year":"2022","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/head.13081","article-title":"The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine","volume":"57","author":"Edvinsson","year":"2017","journal-title":"Headache"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","article-title":"CGRP and migraine: From bench to bedside","volume":"177","author":"Edvinsson","year":"2021","journal-title":"Rev. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","article-title":"An Update: Pathophysiology of Migraine","volume":"37","author":"Goadsby","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u2014Successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Reviews. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/1871527320666211011110307","article-title":"CGRP and CGRP-Receptor as Targets of Migraine Therapy: Brain Prize-2021","volume":"21","author":"Tajti","year":"2022","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tips.2021.01.002","article-title":"Identifying New Antimigraine Targets: Lessons from Molecular Biology","volume":"42","author":"Edvinsson","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","article-title":"Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier","volume":"1600","author":"Eftekhari","year":"2015","journal-title":"Brain Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: A 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","article-title":"Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study","volume":"92","author":"Lipton","year":"2019","journal-title":"Neurology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10072-020-04658-1","article-title":"Erenumab efficacy in highly resistant chronic migraine: A real-life study","volume":"41","author":"Pensato","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","article-title":"Chronic migraine evolution after 3 months from erenumab suspension: Real-world-evidence-life data","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","article-title":"Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: A pooled analysis of placebo-controlled trials","volume":"23","author":"Lampl","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","article-title":"Two-year effectiveness of erenumab in resistant chronic migraine: A prospective real-world analysis","volume":"23","author":"Andreou","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment\u2014Real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03007995.2022.2131299","article-title":"Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine","volume":"39","author":"Mahon","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"687697","DOI":"10.3389\/fneur.2021.687697","article-title":"Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus","volume":"12","author":"Tziakouri","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/head.14196","article-title":"Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study","volume":"61","author":"Spierings","year":"2021","journal-title":"Headache"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1212\/WNL.0000000000010000","article-title":"Effect of fremanezumab on quality of life and productivity in patients with chronic migraine","volume":"95","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","article-title":"Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine","volume":"23","author":"Driessen","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/03331024221076485","article-title":"Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: A pooled analysis of phase 3 studies","volume":"42","author":"Diener","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","article-title":"Efficacy and safety of fremanezumab in clinical trial participants aged \u226560 years with episodic or chronic migraine: Pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies","volume":"22","author":"Nahas","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: A 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-022-01438-4","article-title":"Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: A pooled analysis of phase 3 studies","volume":"23","author":"McAllister","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/head.13970","article-title":"Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and\/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies","volume":"60","author":"Smitherman","year":"2020","journal-title":"Headache"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","article-title":"Long-term treatment with galcanezumab in patients with chronic migraine: Results from the open-label extension of the REGAIN study","volume":"38","author":"Detke","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet. Neurol."},{"key":"ref_98","first-page":"645","article-title":"Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)","volume":"28","author":"Ambrosini","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/13696998.2022.2109335","article-title":"Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: A secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)","volume":"25","author":"Tobin","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1007\/s00415-022-11226-4","article-title":"Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience","volume":"269","author":"Altamura","year":"2022","journal-title":"J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/13696998.2022.2071528","article-title":"Annual indirect cost savings in patients with episodic or chronic migraine: Post-hoc analyses from multiple galcanezumab clinical trials","volume":"25","author":"Tobin","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/head.14257","article-title":"Does \"wearing off\" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials","volume":"62","author":"Ailani","year":"2022","journal-title":"Headache"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: Effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"788159","DOI":"10.3389\/fneur.2021.788159","article-title":"Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine","volume":"12","author":"Mechtler","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: Efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study","volume":"21","author":"Silberstein","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2","volume":"61","author":"Diener","year":"2021","journal-title":"Headache"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/head.14206","article-title":"Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache","volume":"61","author":"Marmura","year":"2021","journal-title":"Headache"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s10194-022-01387-y","article-title":"Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine","volume":"23","author":"Buse","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/ane.13603","article-title":"Eptinezumab for migraine prevention in patients 50 years or older","volume":"145","author":"Martin","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/03331024221077646","article-title":"Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2","volume":"42","author":"Ashina","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s10194-022-01418-8","article-title":"Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2","volume":"23","author":"Apelian","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/head.14295","article-title":"Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention","volume":"62","author":"Lipton","year":"2022","journal-title":"Headache"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/03331024221089567","article-title":"Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine","volume":"42","author":"McAllister","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s10194-022-01482-0","article-title":"Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: Subanalysis of the PROMISE-2 study","volume":"23","author":"Cowan","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kudrow, D., Cady, R.K., Allan, B., Pederson, S.M., Hirman, J., Mehta, L.R., and Schaeffler, B.A. (2021). Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02123-w"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Blumenfeld, A., Ettrup, A., Hirman, J., Ebert, B., and Cady, R. (2022). Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02774-3"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/1440-1681.13700","article-title":"Efficacy and safety of eptinezumab as preventive treatment for episodic\/chronic migraine: A systematic review and meta-analysis","volume":"49","author":"Siahaan","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s13311-021-01128-0","article-title":"Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: A Network Meta-analysis of Randomized Controlled Trials","volume":"18","author":"Yang","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/03331024221111526","article-title":"Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine","volume":"42","author":"Iannone","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","article-title":"Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score","volume":"36","author":"Iannone","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e2662","DOI":"10.1002\/brb3.2662","article-title":"Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies","volume":"12","author":"Nsaka","year":"2022","journal-title":"Brain Behav."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Scuteri, D., Tonin, P., Nicotera, P., Vulnera, M., Altieri, G.C., Tarsitano, A., Bagetta, G., and Corasaniti, M.T. (2022). Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. Toxins, 14.","DOI":"10.3390\/toxins14080529"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/j.pain.0000000000002365","article-title":"Different routes of administration in chronic migraine prevention lead to different placebo responses: A meta-analysis","volume":"163","author":"Swerts","year":"2022","journal-title":"Pain"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40001-022-00716-w","article-title":"Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: A systematic review","volume":"27","author":"Sevivas","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis","volume":"209","author":"Soni","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrneurol.2016.143","article-title":"New strategies for the treatment and prevention of primary headache disorders","volume":"12","author":"Schuster","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14737175.2019.1615447","article-title":"Therapeutic strategies that act on the peripheral nervous system in primary headache disorders","volume":"19","author":"Tajti","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ane.13634","article-title":"Greater occipital nerve block for chronic migraine patients: A meta-analysis","volume":"146","author":"Posso","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/head.12458","article-title":"A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute treatment for chronic migraine","volume":"55","author":"Cady","year":"2015","journal-title":"Headache"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/head.12546","article-title":"Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine","volume":"55","author":"Cady","year":"2015","journal-title":"Headache"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.0000000000002918","article-title":"Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study","volume":"87","author":"Silberstein","year":"2016","journal-title":"Neurology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s10194-015-0543-3","article-title":"Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial","volume":"16","author":"Straube","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/head.13669","article-title":"Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine","volume":"60","author":"Rapoport","year":"2020","journal-title":"Headache"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ane.13034","article-title":"Neurostimulation for the treatment of chronic migraine and cluster headache","volume":"139","author":"Jensen","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/pmt-2021-0038","article-title":"Nerivio((R)) remote electrical neuromodulation for acute treatment of chronic migraine","volume":"12","author":"Nierenburg","year":"2022","journal-title":"Pain Manag."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2004.08.008","article-title":"rTMS of the prefrontal cortex in the treatment of chronic migraine: A pilot study","volume":"227","author":"Brighina","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0333102413515340","article-title":"Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine","volume":"34","author":"Conforto","year":"2014","journal-title":"Cephalalgia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10072-020-04505-3","article-title":"Neuronavigation based 10 sessions of repetitive transcranial magnetic stimulation therapy in chronic migraine: An exploratory study","volume":"42","author":"Kumar","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-022-01428-6","article-title":"Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: A 12-month prospective analysis","volume":"23","author":"Lloyd","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0333102420931050","article-title":"No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial","volume":"40","author":"Grazzi","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neucli.2022.07.005","article-title":"Effects on pain and cognition of transcranial direct current stimulation over the dorsolateral prefrontal cortex in women with chronic migraine","volume":"52","author":"Andrade","year":"2022","journal-title":"Neurophysiol. Clin."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s11739-010-0457-7","article-title":"Chronic migraine: Comorbidities, risk factors, and rehabilitation","volume":"5","author":"Negro","year":"2010","journal-title":"Intern. Emerg. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","article-title":"Psychiatric comorbidities of episodic and chronic migraine","volume":"260","author":"Buse","year":"2013","journal-title":"J. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1526-4610.2008.01185.x","article-title":"Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate","volume":"48","author":"Silberstein","year":"2008","journal-title":"Headache"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11916-012-0304-9","article-title":"Behavioral therapy for chronic migraine","volume":"17","author":"Pistoia","year":"2013","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Grazzi, L., Raggi, A., Guastafierro, E., Passavanti, M., Marcassoli, A., Montisano, D.A., and D\u2019Amico, D. (2022). A Preliminary Analysis on the Feasibility and Short-Term Efficacy of a Phase-III RCT on Mindfulness Added to Treatment as Usual for Patients with Chronic Migraine and Medication Overuse Headache. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192114116"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Lozano-Soto, E., Cruz-Gomez, A.J., Rashid-Lopez, R., Sanmartino, F., Espinosa-Rosso, R., Forero, L., and Gonzalez-Rosa, J.J. (2023). Neuropsychological and Neuropsychiatric Features of Chronic Migraine Patients during the Interictal Phase. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020523"},{"key":"ref_152","first-page":"831035","article-title":"Cutaneous Allodynia in Migraine: A Narrative Review","volume":"12","author":"Quintas","year":"2021","journal-title":"Front. Neurol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/3\/665\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:14Z","timestamp":1760121854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/3\/665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":152,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["life13030665"],"URL":"https:\/\/doi.org\/10.3390\/life13030665","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}